This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Surmodics answers US FTC amended in-house complaint, says GTCR deal is procompetitive

By Wesley Brown ( May 29, 2025, 23:03 GMT | Insight) -- Surmodics answered the US Federal Trade Commission's amended administrative complaint challenging its sale to private equity firm GTCR, stating that the deal is procompetitive and denying the agency’s allegations. The FTC filed an amended complaint on May 14, arguing that a combination of GTCR-held BioCoat and Surmodics would control “over 50 percent of the market for outsourced hydrophilic coatings, which are critical inputs into lifesaving medical devices.”Surmodics answered the US Federal Trade Commission's amended administrative complaint challenging its sale to private equity firm GTCR, stating that the deal is procompetitive and denying the agency’s allegations....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login